Skip to content
Finding a cure for hematologic malignancies with Vor Bio's Dr. Robert Ang  episode artwork

May 15, 2024 43 min

Finding a cure for hematologic malignancies with Vor Bio's Dr. Robert Ang

from Nucleate Singapore Pulse Hosted by Nucleate Singapore

Dr. Robert Ang is the CEO of Vor Bio, a clinical-stage cell and genome engineering therapy company. In this episode, Dr. Ang discusses the challenges of treating cancer, particularly acute myeloid leukemia (AML), and the need for new and innovative approaches. The conversation delves into the challenges of navigating clinical trials during the pandemic and securing funding for research and development. Lastly, he explains how Vor Bio is using cell and gene therapies, such as CAR-T cells and genome engineering, to target AML and potentially cure patients. Host: John Joson Ng Editors: Jessie Wong, John Joson Ng The show notes and transcripts for the episode can be found on nucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to Joson Ng via [email protected]. 01:15 Introduction 07:47 Cancer and treatment modalities 12:02 Vor’s approach to treating AML 31:55 Investing in clinical manufacturing 34:21 Navigating clinical trials and funding during the pandemic 39:53 Looking ahead

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Finding a cure for hematologic malignancies with Vor Bio's Dr. Robert Ang

0:00 43:36

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Nucleate Singapore Pulse?

This episode is 43 minutes long.

When was this Nucleate Singapore Pulse episode published?

This episode was published on May 15, 2024.

Can I download this Nucleate Singapore Pulse episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.